Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for patients with unresectable hepatocellular carcinoma: a cost–utility analysis in China and the United States... by Qiuling Zhao, Yimin He, Zilin Nian, Yongjian Huang, Ruyi Huang, Lijun Lai, Lin Yang

Get full text